Xefocam, 8 mg 30 pcs

XEFOCAM is an NSAID of oxicam class; it has anti-inflammatory, analgesic, antipyretic and antiaggregant effect.

Inhibits proinflammatory factors, decreases platelet aggregation; inhibits COX1 and COX2, disrupts arachidonic acid metabolism, decreases Pg production both in inflammatory focus and healthy tissues; inhibits exudative and proliferative phases of inflammation.

Indications

Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, joint syndrome in gout exacerbation, bursitis, tendovaginitis.

Pain syndrome (mild to moderate intensity): arthralgia, myalgia, neuralgia, lumbago, ischialgia, migraine, toothache and headache, algodysmenorrhea, pain from injuries and burns.

Fever syndrome (“colds” and infectious diseases).

Active ingredient

Composition

1 tablet contains lornoxicam 8 mg.

How to take, the dosage

Xefocam tablets are taken orally before meals with a glass of water.

In moderate to severe pain syndrome: the recommended dose is 8-16 mg/day divided into 2-3 doses; the maximum daily dose is 16 mg.

In inflammatory and degenerative rheumatic diseases: the recommended starting dose is 12 mg; the standard dose is 8-16 mg/day, depending on the patient’s condition.

The duration of therapy depends on the nature and course of the disease.

Interaction

Reduces the effectiveness of uricosuric drugs, increases the effect of anticoagulants, antiaggregants, fibrinolytics, side effects of MKS and GCS, estrogens; reduces the effect of hypotensive drugs and diuretics; increases hypoglycemic effect of sulfonylurea derivatives.

Induces blood concentrations of drugs Li+, methotrexate. Reduces renal clearance of digoxin. Cimetidine increases the plasma concentration of lornoxicam.

Antacids and colestyramine decrease absorption. Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

Special Instructions

The gastrointestinal tract should be monitored during treatment to prevent ulcerogenic effects or gastrointestinal bleeding.

The simultaneous administration of omeprazole or H2-histamine receptor blockers, synthetic Pg analogues (misoprostol) reduces the risk of ulcerogenic effects.

The peripheral blood count and the functional state of the liver and kidneys should be monitored during treatment. In patients with renal insufficiency (plasma creatinine concentration of 150-300 µmol/l) dosage adjustment and regular monitoring of renal function are required.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study. It retains Na+, K+, Li+ and water in the body, which may worsen the course of arterial hypertension and CH, and in persons taking Li+ preparations, increase the severity of side effects of Li+ salts. Elderly patients as well as patients with arterial hypertension need regular BP control.

During treatment, caution should be exercised when driving motor vehicles and engaging in other potentially hazardous activities that require increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Gastrointestinal tract and liver: abdominal pain, diarrhea, dyspepsia, nausea, vomiting; in rare cases – flatulence, dry mouth, gastritis, esophagitis, formation of peptic ulcers and/or bleeding in the GI (including rectal), stomatitis, glossitis, colitis, dysphagia, hepatitis, pancreatitis, liver function disorders.

Allergic reactions: skin rashes, hypersensitivity reactions accompanied by shortness of breath, tachycardia, bronchospasm, Stevens-Johnson syndrome, exfoliative dermatitis, angioitis, fever, allergic rhinitis, lymphadenopathy may occur.

CNS disorders: rarely – dizziness, headache, somnolence, agitation, sleep disturbances, tinnitus, hearing loss, dysarthria, hallucinations, migraine, peripheral neuropathy, syncopal states, aseptic meningitis.

Sensory organs: visual impairment, conjunctivitis.

Peripheral blood and coagulation system disorders: rarely – leukopenia, thrombocytopenia.

Metabolism disorders: rare – increased sweating, chills, weight changes.

Cardiovascular system disorders: rare – arterial hypertension, tachycardia, peripheral edema.

Urinary system disorders: rarely – dysuria, in single cases – glomerulonephritis, papillary necrosis and nephrotic syndrome with transition to acute renal failure, interstitial nephritis, crystalluria, polyuria.

Overdose

Symptoms: increased side effects on the CNS and digestive system, acute renal failure.

Treatment: gastric lavage, activated charcoal, symptomatic therapy. Dialysis is ineffective.

Similarities